Kodiak Sciences Investor Relations Material
Latest events
R&D Day 2024
Kodiak Sciences
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Kodiak Sciences Inc
Access all reports
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of retinal diseases. The company's research and development efforts are centered on novel biologics designed to treat conditions like age-related macular degeneration and diabetic eye diseases, which are major causes of blindness in the developed world. Kodiak's product pipeline includes advanced clinical candidates such as tarcocimab tedromer (KSI-301), which is designed to inhibit vascular endothelial growth factors. Additionally, the company is exploring other candidates targeting different mechanisms involved in retinal diseases. The company is headquartered in Palo Alto, California, and its shares are listed on the NASDAQ.
Key slides for Kodiak Sciences Inc
R&D Day 2024
Kodiak Sciences Inc
R&D Day 2024
Kodiak Sciences Inc
Latest articles
Texas Instruments: From Calculators to Master Capital Allocators
Texas Instruments has undergone many transformations from its origins in oil exploration to become one of the world's largest semiconductor producers.
11 Oct 2024
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Ticker symbol
KOD
Country
🇺🇸 United States